




RealRate

PHARMACEUTICAL 2022

Q32 Bio Inc
Rank 207 of 471

HOMOLOGY
Medicines, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Q32 Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q32 Bio Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Q32 Bio Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 313%, being 38% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	191,909
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,226
Liabilities, Non-Current	24,844
Other Assets	17,560
Other Compr. Net Income	-7.0
Other Expenses	0
Other Liabilities	0
Other Net Income	185
Other Revenues	33,971
Property and Equipment	2,252
Research and Development	93,085
Selling, General and Administrative Expense	36,835

Output Variable	Value in 1000 USD
Assets	211,721
Liabilities	42,070
Expenses	129,920
Revenues	33,971
Stockholders Equity	169,651
Net Income	-95,764
Comprehensive Net Income	-95,768
BaseVar	208,937
ECR before LimitedLiability	216%
Economic Capital Ratio	313%